Novo Holdings acquisition highlights growing pharma commercialization service market, says managing partner

Although it had made several investments in the clinical service market, this is the first time Novo Holdings has ventured into commercialization territory.

Photo: Novo Holdings / PR

The smoke had barely lifted from the New Year fireworks when Novo Holdings announced its first acquisition of 2022 – US company Medical Knowledge Group (MKG).

The firm, which is based in New York and was founded in 2004, has developed a new platform to launch new drugs, and Managing Partner at Novo Holdings Christoffer Søderberg says that this is very interesting in a time when commercializing new drugs is becoming more and more complex.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs